SCHEMBL202844

SCHEMBL202844

NC(=O)c1c(F)ccc(OCc2csc(Nc3ccccc3)n2)c1F

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
SMN1; SMN2 Q16637 4/20 0.47
LMNA P02545 4/20 0.47
KDM4E B2RXH2 2/20 0.47
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
ALDH1A1 P00352 3/20 0.44
MAPK1 P28482 1/20 0.44
GAA P10253 3/20 0.43
HTT P42858 2/20 0.41
VCP P55072 1/20 0.41
CSNK2A1 P68400 1/20 0.40
PLK3 Q9H4B4 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL204397 0.83 SMN1; SMN2 (0.50) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL2316056 0.81 ALDH1A1 (0.52) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL200936 0.80 HTR2A (0.43) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL14777462 0.79 MAPT (0.50) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL2705652 0.77 SLC6A4 (0.49) MAPTLMNAKDM4ENPC1RAB9A
SCHEMBL2706602 0.77 TLR7 (0.43) NPC1RAB9AGAA
SCHEMBL2707295 0.76 LMNA (0.51) MAPTLMNAKDM4EALDH1A1GAA
SCHEMBL2707292 0.76 RAB9A (0.46) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL2706587 0.76 HDAC1 (0.44) SMN1; SMN2LMNA
SCHEMBL2706142 0.75 SCN9A (0.53) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-20130072520-A2 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-03-21 US disclosed
US-20120122918-A1 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2012-05-17 US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122918-A1 ANTIBACTERIAL AGENTS ALK, ROS1, ARG1 MAPT 4688/4885MEN1 1037/4885KMT2A 380/4885
US-20130072520-A2 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 MAPT 4784/4885MEN1 678/4885KMT2A 1011/4885
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 MAPT 4744/4885MEN1 1027/4885KMT2A 415/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 MAPT 4784/4885MEN1 678/4885KMT2A 1011/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 MAPT 4784/4885MEN1 678/4885KMT2A 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.